Advanced Code injection

Ontario Industry Updates

CAAP Company: SYNG Pharmaceuticals and Their Newest Advisor Featured in Kingston News Site

Former MP for Kingston and the Islands Ted Hsu has been spending lots of time with his family since leaving politics behind in 2015, but now he is ready to take on a new challenge.

Hsu is the newest member of SYNG Pharmaceuticals, a Kingston-based company that is looking to help diagnose and treat endometriosis.

Funding Announcement: Ontario Genomics' Genomic Applications Partnership Program (GAPP)

Ontario Genomics iannounced that Round 10 of their Genome Canada’s Genomic Applications Partnership Program is now open.

The Genomic Applications Partnership Program (GAPP) funds public-private research collaborations focused on developing genomics-derived technologies that address opportunities and challenges identified by industry, government, not-for-profits or other “Receptors” of genomics knowledge and tools.

EOI forms are due to Ontario Genomics on November 13th, 2017 at 9 am ET.

Information and Application

Canadian Space Agency Information Session, Oct 26 2017 In Toronto

The Canadian Space Agency (CSA), in partnership with the National Research Council of Canada's Industrial Research Assistance Program (IRAP), wishes to engage the biomedical, health and performance communities as well as space stakeholders to help identify potential Canadian health and biomedical roles in human deep space missions, and explore new ways to collaborate to improve the innovation process in both space and terrestrial health.

Interface Biologics Enters the Neurology Market with 510(k) Clearance of Arkis BioSciences® CerebroFlo™ EVD Catheter with Endexo® Technology

TORONTO, ONTARIO Sept. 26, 2017 - Interface Biologics, a privately held, commercial stage company developing innovative material science technologies that save lives and improve patient outcomes, is pleased to announce that Arkis BioSciences® has received 510(k) clearance from U.S. Food and Drug Administration (FDA) for its exclusive CerebroFlo™ EVD Catheter with IBI's Endexo® technology.

Lumira Capital Leads $7M Series A Financing of Edesa Biotech

MARKHAM, ON, Sept. 20, 2017 Edesa Biotech Inc., a clinical-stage private company announced today the completion of a $7 million Series A financing.  The internationally syndicated investment was led by Lumira Capital and included participation from Pharmascience Inc., Inveready Technology Investment Group and a number of Canadian family offices.

CAAP Company: Proteorex Presents at IndieBio's Demo Day

IndieBio is the world’s largest biotechnology accelerator, and Proteorex presented as part of the Batch 5 Cohort. The company is is developing small molecule drugs for challenging targets implicated in diseases with the highest unmet need. 

The presentation was delivered in San Francisco this September 14th by Dr. Marc Adler, Co-Founder and Technology Director of Proteorex.

Mars Innovation and Evotec Ag Establish Academic Bridge “Lab150” in Toronto

MaRS Innovation and Evotec AG today announced the launch of “LAB150”.  This transformational Toronto-based partnership will give Canada access to the world-class infrastructure and drug discovery expertise of Evotec, and pair it with cutting-edge drug discovery projects emerging from the 15 Member institutions of MaRS Innovation.

Lab150 is a joint effort by MaRS Innovation and Evotec AG selection and acceleration of early-stage drug discovery projects originating from leading academic institutions and teaching hospitals in Toronto (Canada)

Quick Biotechnology Survey on Employee Perception of the Workplace

Biotechnology Focus, in collaboration with Stratford Managers Corporation, wants to learn more about employee perception of their workplace.

Please complete the survey in its entirety before September 22nd. The responses will be included in in a sector report that will be featured in the October/November issue of Biotechnology Focus.

To start the Survey click here

Seed Funding Available: Weston Brain Institute Launches Rapid Response - Canada 2018 Program for Parkinson’s & Related Diseases

Program Overview

Seed funding for novel, high-risk, high-reward translational research to accelerate the development of safe and effective treatments for neurodegenerative diseases of aging. Funding up to $200,000 over up to 18 months

Letter of Intent Deadline: December 4, 2017 at 2pm EST

Program Information Session: October 10, 2017 at 1pm EDT (Register here)

Application Form

CAAP Company: MyndTec Announces 510(k) Clearance for MyndMove® Therapy for Individuals with Upper Extremity Paralysis

MyndTec, an award-winning Canadian medical technology company announced today it has received 510(k) clearance to market its landmark product MyndMove®.  MyndTec is a pioneer in the treatment of arm and hand paralysis caused by stroke or spinal cord injury. 

This is a major milestone in the evolution of our company. We are delighted that we can now offer this life-changing therapy to patients in the U.S. with upper extremity paralysis.
— Dr. Milos R. Popovic, MyndTec Founder

For the full press release click here

CAAP Companies: Komodo OpenLab & KE2 Technologies Advance to the Top 10 in the Interface Health Challenge

The 3rd annual INTERFACE HEALTH CHALLENGE X 2017 (#IHCX2017 competition seeks to find the world’s most innovative digital health start-ups.

This year CAAP companies KomodoOpenLab and KE2 Technologies have made it to the Top 10, guaranteeing a cash prize and putting them in contention for the $40K 1st Prize.